Sugi Predict

Sugi Predict / Compounds / SCHEMBL4764459

SCHEMBL4764459

SCHEMBL4764459

Fc1ccc(Nc2ncnc3[nH]c(-c4ccc(CN5CCCCC5)cc4)cc23)cc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 17/20 0.59
▸ CSF1R P07333 3/20 0.51
▸ ERBB2 P04626 4/20 0.50
▸ ERBB4 Q15303 3/20 0.50
▸ KDR P35968 2/20 0.50
▸ STK10 O94804 1/20 0.50
▸ MAP4K4 O95819 1/20 0.50
▸ ABL1 P00519 1/20 0.50
▸ YES1 P07947 1/20 0.50
▸ RET P07949 1/20 0.50
▸ PDGFRB P09619 1/20 0.50
▸ BCR P11274 1/20 0.50
▸ FLT1 P17948 1/20 0.50
▸ ERBB3 P21860 1/20 0.50
▸ WEE1 P30291 1/20 0.50
▸ ABL2 P42684 1/20 0.50
▸ NEK3 P51956 1/20 0.50
▸ LIMK1 P53667 1/20 0.50
▸ LIMK2 P53671 1/20 0.50
▸ EPHB4 P54760 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4769176 0.99 EGFR (0.58) EGFRCSF1RERBB2ERBB4KDR
SCHEMBL27603090 0.93 CSF1R (0.52) EGFRCSF1RERBB2ERBB4KDR
SCHEMBL4766665 0.92 EGFR (0.54) EGFRERBB2ERBB4KDRSTK10
SCHEMBL4765901 0.91 EGFR (0.54) EGFRERBB2ERBB4KDRSTK10
SCHEMBL4766999 0.91 EGFR (0.62) EGFRCSF1RERBB2ERBB4KDR
SCHEMBL4764690 0.91 AXL (0.56) EGFRCSF1RERBB2ERBB4KDR
SCHEMBL4763961 0.91 CSF1R (0.63) EGFRCSF1RERBB2ERBB4KDR
SCHEMBL4764252 0.87 EGFR (0.51) EGFRERBB2ERBB4JAK3
SCHEMBL4766474 0.86 CSF1R (0.46) EGFRCSF1RERBB2ERBB4KDR
SCHEMBL4769443 0.85 EGFR (0.54) EGFRERBB2ERBB4KDRJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101560214-A 4-amino-6-phenyl-pyrrolo[2, 3-d]pyrimidine derivatives NOVARTIS AG (CH) 2009-10-21 — — CN claimed
EP-1416935-B1 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2008-03-12 — — EP claimed
US-7244729-B2 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives NOVARTIS AG (CH) 2007-07-17 — — US claimed
US-20040248911-A1 7H-pyrrolo[2,3-d]pyrimidine derivatives BOLD GUIDO (CH) 2004-12-09 — — US claimed
US-20040242600-A1 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives NOVARTIS AG (CH) 2004-12-02 — — US claimed
CN-1538847-A 4-amino-6-phenyl-pyrrolo [2, 3-d ] pyrimidine derivatives ��˹��ŵ�� 2004-10-20 — — CN claimed
CN-101560214-B 4-amino-6-phenyl-pyrrolo[2, 3-d]pyrimidine derivatives NOVARTIS AG 2011-05-25 — — CN disclosed
CN-101560214-A 4-amino-6-phenyl-pyrrolo[2, 3-d]pyrimidine derivatives NOVARTIS AG (CH) 2009-10-21 — — CN disclosed
EP-1416935-B1 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2008-03-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248911-A1 7H-pyrrolo[2,3-d]pyrimidine derivatives DPYD, DHPS, TYMP EGFR 3391/4885CSF1R 3024/4885ERBB2 2012/4885
US-20040242600-A1 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives DPYD, TYMP, TYMS EGFR 2694/4885CSF1R 3516/4885ERBB2 1341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.